Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2026
Reporting Period: Event date May 13, 2026
The Company is a Delaware corporation with its principal executive offices in High Point, NC. Its Class A common stock trades on the Nasdaq Capital Market under the symbol "VTVT".
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Item 8.01 - Other Events: On May 13, 2026, the Company filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its previously-announced at-the-market (ATM) sales program to the full amount provided for under the program.
Legal Opinion: In connection with the ATM Program, the Company filed a legal opinion from Dechert LLP regarding the legality of the Class A common stock issuable under the program. This opinion is attached as Exhibit 5.1 and incorporated by reference into the Company's effective shelf Registration Statement on Form S-3.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, specific risk factors, or contingencies beyond the standard disclosure of the ATM program expansion and the associated legal opinion.
Investor Verification Checklist
- Verify the total number of shares authorized under the ATM Program in the effective Form S-3 Registration Statement.
- Review the legal opinion from Dechert LLP (Exhibit 5.1) attached to this filing for any conditions on the issuance of shares.
- Monitor future filings for actual sales volumes and proceeds generated under the expanded ATM Program.
- Confirm the current share count and potential dilution impact based on the full amount now available for sale.